Rexulti Insurance Denied? How to Appeal Your Brexpiprazole Denial

Rexulti (brexpiprazole) is an atypical antipsychotic FDA-approved for major depressive disorder (as adjunctive therapy with antidepressants), schizophrenia, and agitation associated with Alzheimer's dementia. It is related to aripiprazole (Abilify) but has a distinct receptor binding profile that offers a different tolerability and efficacy balance. Insurance companies frequently deny Rexulti, citing the availability of generic alternatives or insufficient prior therapy trials. Here's how to fight back.

What Rexulti Treats and Why Patients Need It

Rexulti is a dopamine D2/D3 and serotonin 5-HT1A partial agonist and 5-HT2A antagonist — a mechanism shared with aripiprazole but with different receptor affinities that translate to a distinct clinical profile.

FDA-approved for:

• Adjunctive treatment of MDD in adults: used alongside an antidepressant when the antidepressant alone provides insufficient relief
• Schizophrenia in adults and adolescents aged 13 and older
• Agitation associated with Alzheimer's dementia in adults — received FDA approval in 2023

For MDD patients who have a partial response to antidepressants, Rexulti can provide meaningful additional improvement in mood, anxiety, and function. For schizophrenia patients, it controls positive and negative symptoms. For Alzheimer's patients with severe agitation, it is now the only FDA-approved pharmacological treatment specifically for this indication.

Common Denial Reasons for Rexulti

Step therapy — generic atypicals first: Plans typically require failure of generic atypical antipsychotics (aripiprazole, quetiapine, olanzapine) before approving Rexulti. For MDD augmentation, plans may also require failure of specific generic augmentation agents like lithium, buspirone, or generic aripiprazole.

MDD augmentation indication not covered: Some plans have narrow coverage for antipsychotic augmentation of MDD, or require additional documentation of antidepressant trial history.

Schizophrenia indication: preferred generic not tried: Plans prefer cheaper generic antipsychotics for schizophrenia.

Alzheimer's agitation indication newly approved: Plans may not have updated their formularies to reflect the 2023 FDA approval for Alzheimer's agitation.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization missing documentation: Missing diagnosis, severity, and prior treatment documentation.

Step-by-Step: How to Appeal a Rexulti Denial

Step 1: Identify the denial reason and indication. MDD, schizophrenia, or Alzheimer's agitation have different appeal strategies.

Step 2: For MDD augmentation: Document your antidepressant history (two adequate trials) AND your augmentation history (trials of lithium, buspirone, generic aripiprazole or quetiapine, thyroid hormone) if required. Specific reasons these agents failed — adverse effects, partial response, intolerance — should be documented.

Step 3: For schizophrenia: Document prior antipsychotic trials (generic risperidone, aripiprazole, olanzapine, quetiapine) with specific reasons for failure — lack of efficacy, metabolic side effects (weight gain, diabetes), prolactin elevation, EPS.

Step 4: For Alzheimer's agitation: Note the FDA approval date (May 2023) and that Rexulti is the only FDA-approved pharmacological treatment specifically for Alzheimer's agitation. Include documentation of non-pharmacological interventions tried.

Step 5: Have your psychiatrist or neurologist write a Letter of Medical Necessity appropriate to the indication.

Step 6: Submit the internal appeal and request peer-to-peer review.

Step 7: File an external appeal if needed.

What to Include in Your Rexulti Appeal Letter

• Policy number, member ID, and claim reference
• Rexulti (brexpiprazole) dose and specific indication
• For MDD: antidepressant history and augmentation history with outcomes
• For schizophrenia: prior antipsychotic trials with specific reasons for failure
• For Alzheimer's agitation: NPI (Neuropsychiatric Inventory) agitation scores, non-pharmacological interventions tried, FDA approval citation
• Letter of Medical Necessity from psychiatrist or neurologist
• FDA approval citations for each applicable indication
• Clinical rationale for brexpiprazole over generic alternatives
• Request for peer-to-peer review

Success Tips for Rexulti Appeals

Document metabolic side effects from generic antipsychotics. Weight gain, elevated cholesterol, elevated blood sugar, and new-onset diabetes are serious adverse effects of many generic atypical antipsychotics (particularly olanzapine, quetiapine, and clozapine). Rexulti has a more favorable metabolic profile. If prior agents caused these issues, document them with labs.

For Alzheimer's agitation, emphasize the "only approved" argument. As the only FDA-approved medication specifically for Alzheimer's-associated agitation, Rexulti occupies a unique position in the treatment algorithm. Other antipsychotics used for this indication are off-label and carry black box warnings about mortality in elderly dementia patients — Rexulti received approval based on a specific risk-benefit assessment for this population.

EPS and tardive dyskinesia history matters. If a patient has experienced extrapyramidal symptoms (EPS) or tardive dyskinesia on prior antipsychotics, this is a documented adverse effect that can justify selecting a lower-EPS-risk alternative.

Quantify the MDD inadequate response. PHQ-9 scores remaining above 10 despite antidepressant therapy demonstrate insufficient control that justifies augmentation.

Fight Back With ClaimBack

Rexulti is prescribed for serious conditions — depression that hasn't responded to antidepressants, schizophrenia, and Alzheimer's agitation. ClaimBack helps you build a complete, well-documented appeal to fight for the medication your doctor prescribed.

Start your Rexulti appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals